COPENHAGEN, Denmark, March 17, 2021— Vipergen ApS today announced the appointment of Leif Kongskov Larsen, Ph.D. as Director of Biology, and the promotion of Allan Beck Christensen, Ph.D., to Director of Screening Technology. Dr. Larsen and Dr. Christensen will report directly to Nils Hansen, Ph.D. Vipergen’s CEO. Dr. Larsen and Dr. Christensen will be members of Vipergen’s leadership team.
Dr Larsen has an extensive experience in biology and drug discovery with over 20 years of industrial experience. Most recently, Dr. Larsen was group leader at Gubra, focusing on assays and sequencing. Prior to this he spent 3 years at the Danish Medicines Agency as a group head controlling biological pharmaceuticals. Prior to this he spent 5 years at Vipergen latest as a group head focusing on assays, sequencing and screening. Dr Larsen will lead the Biology group and will be a member of Vipergen’s leadership team.
Dr Christensen has been with Vipergen since 2010 in various roles with increasing responsibilities, and he has played a pivotal role in the development of the Vipergen’s screening technologies, including the recently implemented and commercialized Cellular Binder Trap Enrichment platform. He will lead the Screening Technologies group and will be a member of Vipergen’s leadership team.
“Leif and Allan provide tremendous insights and deep skill sets to Vipergen, and we are delighted to have both on board in our leadership team,” said Nils Hansen, Ph.D., Vipergen’s chief executive officer. “Their support is integral to our goal of further advancing small molecule drug discovery by cutting edge DNA-encoded library technologies.”
“Vipergen has demonstrated its drug discovery competencies across its many partnerships” said Leif Kongskov Larsen. “The team has developed unique and comprehensive technologies and capabilities for finding novel and tractable hits for even challenging targets. I am delighted to be part of the team again. I look forward to contributing to the further advancements.”
“It’s exciting times at Vipergen” said Allan Beck Christensen. “We have further innovated our technologies allowing even better and faster hit finding. I look forward to continue to contribute to the further development.”
About Vipergen ApS
Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies as a service to biotechnology and pharmaceutical company partners, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor®, Binder Trap Enrichment®, and Cellular Binder Trap Enrichment® drug discovery technology platforms, please visit www.vipergen.com.
Vipergen Contact:
Nils Hansen, Ph.D., Chief Executive Officer
Vipergen ApS
Email: nha@vipergen.com
Phone: +45 2523 6680